Over time, there has been increasing recognition of the importance of preservation of residual kidney function (RKF) in dialysis patients (1) . The presence of RKF has been shown to contribute to the overall health and wellbeing of dialysis patients including improved survival, better nutrition, and reduced inflammation (2) (3) (4) . Compared to patients receiving peritoneal dialysis, the importance of RKF among patients receiving hemodialysis has been relatively less appreciated and mostly disregarded at the commencement of hemodialysis, given prior reports that RKF declines more rapidly following hemodialysis initiation (5, 6) . However, contrary to popular belief, rapid decline of RKF does not necessarily occur after transitioning to hemodialysis, although those who are receiving this modality may be at risk of RKF loss owing to potential intradialytic hypotension, nephrotoxic drugs, and coexisting comorbidities (e.g., congestive heart failure) (7) . Moreover, given growing evidence demonstrating robust associations between RKF and survival in hemodialysis patients, preservation of RKF has become a valid therapeutic goal in this population (2, 8) .
Traditionally, the thrice-weekly hemodialysis start has been considered as the standard treatment regimen for initiation of therapy among incident hemodialysis patients regardless of their RKF. It is not clear, however, why dialysis should be "started" abruptly, as opposed to a gradual "transition" to dialysis, using approaches such as less frequent dialysis treatment including twice-weekly hemodialysis (9) . In the English language, there are indeed fundamental differences in meaning between the terminology "start" vs. "transition" (see Figure 1 ). Based on the 2006 Kidney Disease Outcome Quality Initiative (KDOQI) Clinical Practice Guidelines, Guideline 4.3.2., twice-weekly hemodialysis is not appropriate for patients with renal urea clearance (Kr) <2 mL/min/1.73 m 2 , while the Work Group advised that thrice-weekly hemodialysis as a minimum frequency level was no longer appropriate (10) .
Based on solute kinetics, the KDOQI Work Group was comfortable recommending a twice-weekly dialysis schedule among patients with substantial RKF, defined as those with a Kr >3 mL/min to be initiated on twice-weekly hemodialysis, and those with a Kr >2 mL/min who will maintain this regimen (see Figure 2 ).
Recently, several observational studies have shown that twice-weekly hemodialysis is associated with better preservation of RKF and higher health-related quality of life (11, 12) . These findings have sparked greater interest in considering twice-weekly hemodialysis as an initial dialysis prescription. In addition, twice-weekly hemodialysis has demonstrated similar survival rates compared to that of Figure 1 Comparing the definitions of "start" versus "transition" in order to better understand the concepts of "starting" dialysis abruptly as thrice-weekly hemodialysis versus incrementally "transitioning" to dialysis as twice-weekly hemodialysis (9) .
Figure 2
The KDOQI guidelines pertaining to the recommended frequency of hemodialysis treatment per week based on residual kidney function defined by renal urea clearance (Kr) (10) .
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Ann Transl Med 2018;6(16):317 atm.amegroups.com thrice-weekly hemodialysis among patients with substantial RKF (11) . Given these findings, clinical practice guidelines allowed for the use of twice-weekly hemodialysis among patients with substantial RKF and have recently increased the weight of RKF incorporated into dialyzer Kt/V to calculate standard Kt/V urea (13) .
The beneficial impact of RKF on patient outcomes may be related to improved volume control and greater solute clearance, particularly that of middle molecules and protein-bound solutes (14, 15) . Traditionally, Kt/V urea, small solute clearance has been the standard metric for measuring dialysis adequacy. However, higher dialyzer urea clearance (high-dose Kt/V urea ) failed to improve patient outcomes in the Hemodialysis (HEMO) study (16) . This may be in part due to inadequate removal of uremic solutes other than urea by hemodialysis alone. Furthermore, the characteristics of solute clearance offered by dialysis vs. RKF are different.
For example, protein-bound solutes are largely secreted by organic acid transporters in the proximal renal tubule, and so removed by the kidney (17) . One concern regarding the prescription of twice-weekly hemodialysis has been (15, 19) .
Furthermore, the authors concluded that plasma levels of these solutes can be well controlled by twice-weekly hemodialysis in patients with RKF to the same degree as thrice-weekly hemodialysis in anuric patients. However, the relative importance of RKF on clearance rates can vary among secreted solutes; it was greater for hippurate and phenylacetylglutamine than for indoxyl sulfate and p-cresol sulfate in this study. The variability of residual clearance for different secreted solutes has been observed in previous studies (20) . This may be explained by the differential degree of protein binding, reduced availability for transporters, and biologic variability in protein expression of transporters among different solutes.
Although the clearance of middle molecules such as β2microglobulin may be enhanced by some hemodialysis techniques, increasing treatment adequacy or frequency of hemodialysis is largely limited or ineffective in improving the clearance of secreted solutes (16, 21, 22) . Moreover, these approaches may potentially lead to more accelerated decline in RKF (23) . Hence, preserving RKF in hemodialysis patients may be more effective in removing secreted solutes as opposed to increasing the frequency of hemodialysis. were anuric on thrice-weekly hemodialysis. In an analysis of the HEMO study cohort who largely had little to no RKF, hippurate, p-cresol sulfate, indoxyl sulfate, and phenylacetylglutamine concentrations were not associated with cardiovascular outcomes (24) . However, some studies have suggested that uremic toxicity and adverse clinical outcomes may ensue from these solutes (17, 25) . Therefore, an adequately powered clinical trial is needed to determine whether twice-weekly hemodialysis among patients with higher RKF will result in greater preservation of RKF and improved patient outcomes beyond that of reduced concentrations of circulating secreted solutes. In addition, further studies are needed to identify adjuvant strategies that will best preserve residual function among patients with substantial RKF who initiate twice-weekly hemodialysis.
In summary, the study by Leong et al. provides reassuring evidence that twice-weekly hemodialysis in patients with RKF is associated with similar plasma concentrations of secreted solutes and near-equivalent dialysis adequacy as thrice-weekly hemodialysis in anuric patients. As discussed by the investigators, these results may affirm recently updated guidelines that have given greater weight to RKF in calculating total clearance and adequacy, and may also inspire further studies that incorporate assessment of RKF in the prescription of dialysis.
